Xencor Inc
NASDAQ:XNCR

  • LAST PRICE
    21.0900
  • TODAY'S CHANGE (%)
    -0.1100 (-0.5189%)
  • Bid / Lots
    20.7700/ 10
  • Ask / Lots
    21.3700/ 10
  • Open / Previous Close
    21.1400 / 21.2000
  • Day Range
    20.8600
    21.2500
  • 52 Week Range
    15.3100
    26.8400
  • Volume
    1,363,143

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Sep 12, 2024

      Show headlines and story abstract

    • 4:22PM ET on Thursday Sep 12, 2024 by MT Newswires
      Companies Mentioned: XNCR
      04:22 PM EDT, 09/12/2024 (MT Newswires) -- Xencor (XNCR) said late Thursday it has raised about $201.3 million from the public offering of its shares and pre-funded warrants, including the exercise in full by its underwriters of an over-allotment op...

    • 4:01PM ET on Thursday Sep 12, 2024 by Dow Jones
      Companies Mentioned: XNCR
      PASADENA, Calif.--(BUSINESS WIRE)--September 12, 2024--
      Xencor, Inc. ("Xencor") (Nasdaq: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the closing of its previously announced underwritten public offering of 8,093,712 shares of its common stock at a price to the public of $18.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 1,458,600 additional shares of common stock, and pre-funded warrants to purchase up to an aggregate of 3,088,888 shares of common stock at a price to the public of $17.99 per pre-funded warrant. The pre-funded warrants are immediately exercisable and have an exercise price of $0.01 per share. The gross proceeds to Xencor from this offering were approximately $201.3 million, before deducting underwriting discounts and commissions and offering expenses.

  • Sep 11, 2024

      Show headlines and story abstract

    • 10:22AM ET on Wednesday Sep 11, 2024 by Dow Jones
      Companies Mentioned: XNCR

      By Dean Seal

      Shares of Xencor jumped after the company said its underwritten public offering was priced to raise $175 million.

      The stock price was up 10% at $21.04 early Wednesday. Shares are about flat with where they started the year.

    • 7:09AM ET on Wednesday Sep 11, 2024 by MT Newswires
      Companies Mentioned: XNCR
      07:09 AM EDT, 09/11/2024 (MT Newswires) -- Xencor (XNCR) said Wednesday that it priced its underwritten public offering of about 6.6 million shares of its common stock at $18 per share and pre-funded warrants to buy up to about 3.1 million shares of...

    • 6:31AM ET on Wednesday Sep 11, 2024 by Dow Jones
      Companies Mentioned: XNCR
      PASADENA, Calif.--(BUSINESS WIRE)--September 11, 2024--
      Xencor, Inc. ("Xencor") (Nasdaq: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the pricing of its underwritten public offering of (i) 6,635,112 shares of its common stock at a price to the public of $18.00 per share and (ii) pre-funded warrants to purchase up to an aggregate of 3,088,888 shares of common stock at a price to the public of $17.99 per pre-funded warrant. The pre-funded warrants will be immediately exercisable and will have an exercise price of $0.01 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $175 million. Xencor has also granted the underwriters a 30-day option to purchase up to 1,458,600 additional shares of its common stock. All of the shares of common stock and pre-funded warrants in the offering are to be sold by Xencor. The offering is expected to close on or about September 12, 2024, subject to the satisfaction of customary closing conditions.

Peers Headlines